Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.

EEG Connectivity and Graph Theory Combined With ApoE Testing

Method of Measurement (Pre-analytical Tools)
Imaging
Biomarker Measured
Cell signaling
Use
Susceptibility/risk
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Primary aim of the present project is to investigate the dynamic connectivity among brain centers by using a mathematical (Small World) approach to the analysis of EEG-related neural networks. The aim is to provide reliable discrimination of amnesic-Mild Cognitive Impairment (a MCI) subjects who, on individual basis, will rapidly convert to Alzheimer Disease (AD) after a relatively brief follow-up. Moreover, keeping in mind that the epsilon-4 allele of the ApoE gene is a genetically determined risk factor for pathogenesis of late-onset AD, a secondary endpoint is introduced to investigate whether the EEG connectivity markers together with a genetically determined risk of dementia as represented by ApoE testing can reach higher sensitivity/specificity for early discrimination of MCI converting to AD

Target Population/ Population Being Studied

Participants witn aMCI

Length of Current Trial
2 years
Number of Trial Participants

150

Estimated Trial Completion
September 2020
What is Required from Patients

wearing noninvasive EEG cap for the in clinic visit

What is Required from the Health System

EEG, EEG technician, statistical calculator

Sponsor

Catholic University of the Sacred Heart

“Sustainable Method for Alzheimer's Prediction.” ClinicalTrials.gov. Accessed October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT03654911?term=biomarker&recrs=b&cond=Alzheimer+Disease&rank=2